ARCT
ARCT
Positions held
Your positionsARCT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-25 · Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
2026-09-24 · CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls
2026-09-24 · Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8
2026-08-31 · Arcturus Therapeutics to Participate in Upcoming Investor Conferences
2026-08-27 · Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
2026-08-21 · Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
2026-08-20 · Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
2026-08-12 · Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-06 · Arcturus Therapeutics Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns